Gastrointestinal symptoms associated with gastroesophageal reflux disease, and their relapses after treatment with proton pump inhibitors
A systematic review
Keywords:
Gastroesophageal reflux disease (GERD), Proton pump inhibitors (PPI), Comorbidities, RelapseAbstract
Gastroesophageal reflux disease (GERD) is a common functional gastrointestinal disorder with significant effects on the quality of life. The burden of GERD is soaring in Asia. Preventing symptom relapse is a therapeutic goal in GERD patients. Since proton pump inhibitors (PPI) are the first-line treatment of GERD, drug failure has become a major problem in the treatment procedure. We reviewed the literature in order to find articles related to comorbidities and symptoms affecting GERD from 1980 to 2015 via PubMed and Google Scholar using keywords such as ‘Gastroesophageal reflux disease’, ‘Gastrointestinal symptoms’ and Boolean operators (such as AND, OR, NOT). Due to the cost of PPI therapy and the high rate of GERD relapse after PPI therapy, demand for continuing this type of treatment is decreasing. Thus, we need to discover new approaches to treat the disease and also investigate the relationship between the treatment of GERD and its comorbidities and symptoms such as functional constipation.
References
Bergmann MM, Caubet JC, McLin V, Belli DC, Schappi MG, Eigenmann PA. Common colic,
gastroesophageal reflux and constipation in infants under 6 months of age do not necessitate an allergy
work-up. Pediatr Allergy Immunol. 2014; 25(4): 410-2. doi: 10.1111/pai.12199. PMID: 24438166.
Indrio F, Di Mauro A, Riezzo G, Cavallo L, Francavilla R. Infantile colic, regurgitation, and constipation:
an early traumatic insult in the development of functional gastrointestinal disorders in children?. Eur J
Pediatr. 2015; 174(6): 841-2. doi: 10.1007/s00431-014-2467-3. PMID: 25504357.
Tighe M, Afzal N, Bevan A, Hayen A, Munro A, Beattie R. Pharmacological treatment of children with
gastro-oesophageal reflux. Cochrane Database Syst Rev. 2014; 24(11). doi:
1002/14651858.CD008550.pub2. PMID: 25419906.
Chiu CT, Hsu CM, Wang CC, Chang JJ, Sung CM, Lin CJ, et al. Randomised clinical trial: sodium alginate
oral suspension is non-inferior to omeprazole in the treatment of patients with non-erosive
gastroesophageal disease. Aliment Pharmacol Ther. 2013; 38(9): 1054-64. doi: 10.1111/apt.12482. PMID:
5) Yoshida N, Kamada K, Tomatsuri N, Suzuki T, Takagi T, Ichikawa H, et al. Management of recurrence of
symptoms of gastroesophageal reflux disease: synergistic effect of rebamipide with 15 mg lansoprazole.
Dig Dis Sci. 2010; 55(12): 3393-8. doi: 10.1007/s10620-010-1166-9. PMID: 20198424.
Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure in gastro- oesophageal reflux disease-where next?. Aliment Pharmacol Ther. 2005; 22(2): 79-94. doi: 10.1111/j.1365- 2036.2005.02531.x. PMID: 16011666.
Zeng J, Zuo XL, Li YQ, Wei W, Lv GP. Tegaserod for dyspepsia and reflux symptoms in patients with
chronic constipation: an exploratory open-label study. Eur J Clin Pharmacol. 2007; 63(6): 529-36. doi:
1007/s00228-007-0287-3. PMID: 17468863.
Jiang X, Lu FF, Wang WC, Liu YL. The characteristics of gastroesophageal reflux disease overlapping
with functional bowel diseases in gastrointestinal clinic. Zhonghua Nei Ke Za Zhi. 2013; 52(10): 806-10.
PMID: 24378054.
Rasmussen S, Jensen TH, Henriksen SL, Haastrup PF, Larsen PV, SÃ ndergaard J, et al. Overlap of
symptoms of gastroesophageal reflux disease, dyspepsia and irritable bowel syndrome in the general
population. Scand J Gastroenterol. 2015; 50(2): 162-9. doi: 10.3109/00365521.2014.983157. PMID:
Hosseini M, Salari M, Salari R. Psyllium seed may be effective in the treatment of gastroesophageal reflux
disease (GERD) in patients with functional constipation. J Med Hypotheses Ideas. 2015; 9: S4–S7. doi:
1016/j.jmhi.2015.11.002.
Lee SY, Lee KJ, Kim SJ, Cho SW. Prevalence and risk factors for overlaps between gastroesophageal
reflux disease, dyspepsia, and irritable bowel syndrome: a population-based study. Digestion. 2009; 79(3):
-201. doi: 10.1159/000211715. PMID: 19342860.
Vakil N, Niklasson A, Denison H, Ryden A. Symptom profile in partial responders to a proton pump
inhibitor compared with treatment-naïve patients with gastroesophageal reflux disease: a post hoc analysis
of two study populations. BMC gastroenterology. 2014; 14: 177. doi: 10.1186/1471-230X-14-177. PMID:
, PMCID: PMC4287106.
Kua CH, Ng ST, Lhode R, Kowalski S, Gwee KA. Irritable bowel syndrome and other gastrointestinal
disorders: evaluating self-medication in an Asian community setting. Int J Clin Pharm. 2012; 34(4): 561-8.
doi: 10.1007/s11096-012-9644-0. PMID: 22552577.
Yarandi SS, Nasseri-Moghaddam S, Mostajabi P, Malekzadeh R. Overlapping gastroesophageal reflux
disease and irritable bowel syndrome: increased dysfunctional symptoms. World journal of
gastroenterology: World J Gastroenterol. 2010; 16(10): 1232. PMID: 20222167, PMCID: PMC2839176.
Lovell RM, Ford AC. Prevalence of gastro-esophageal reflux-type symptoms in individuals with irritable
bowel syndrome in the community: a meta-analysis. Am J Gastroenterol. 2012; 107(12): 1793-801. doi:
1038/ajg.2012.336. PMID: 23032982.
Barratt SM, Leeds JS, Robinson K, Shah PJ, Lobo AJ, McAlindon ME, et al. Reflux and irritable bowel
syndrome are negative predictors of quality of life in coeliac disease and inflammatory bowel disease. Eur J
Gastroenterol Hepatol. 2011; 23(2): 159-65. doi: 10.1097/MEG.0b013e328342a547. PMID: 21178777.
de Bortoli N, Martinucci I, Bellini M, Savarino E, Savarino V, Blandizzi C, et al. Overlap of functional
heartburn and gastroesophageal reflux disease with irritable bowel syndrome. World J Gastroenterol. 2013;
(35): 5787. doi: 10.3748/wjg.v19.i35.5787. PMID: 24124323, PMCID: PMC3793133.
Lim CH, Choi MG, Baeg MK, Moon SJ, Kim JS, Cho YK, et al. Symptom characteristics and
psychosomatic profiles in different spectrum of gastroesophageal reflux disease. Gut liver. 2014; 8(2): 165- 9. doi: 10.5009/gnl.2014.8.2.165, PMCID: PMC3964267.
Marlais M, Fishman JR, Koglmeier J, Fell JME, Rawat DJ. Reduced quality of life in children with Gastro- oesophageal reflux disease. Acta Paediatr. 2010; 99(3): 418-21. doi: 10.1111/j.1651-2227.2009.01613.x.
PMID: 19930192.
Pimentel M, Rossi F, Chow EJ, Ofman J, Fullerton S, Hassard P, et al. Increased prevalence of irritable
bowel syndrome in patients with gastroesophageal reflux. J Clin Gastroenterol. 2002; 34(3): 221-4. PMID:
Pourhoseingholi A, Ashtari S, Pourhoseingholi MA, Moghimi-Dehkordi B, Safaee A, Zali MR. Irritable
bowel syndrome, gastro-oesophageal reflux disease and dyspepsia: Overlap analysis using loglinear
models. Arab J Gastroenterol. 2012; 13(1): 20-3. doi: 10.1016/j.ajg.2012.02.005. PMID: 22560820.
Salari R, Yousefi M, Salari M. Pharmacological treatment of chronic constipation: a literature review. Rev
Clin Med. 2016; 3(3): 128-132. doi: 10.22038/rcm.2016.6818.
Zeitoun JD, Lefevre JH, de Parades V, Sejourne C, Sobhani I, Coffin B, et al. Functional Digestive
Symptoms and Quality of Life in Patients with Ehlers-Danlos Syndromes: Results of a National Cohort
Study on 134 Patients. PloS one. 2013; 8(11): e80321. doi: 10.1371/journal.pone.0080321. PMID:
, PMCID: PMC3838387.
Chitkara DK, Talley NJ, Weaver AL, Katusic SK, De Schepper H, Rucker MJ, et al. Incidence of
presentation of common functional gastrointestinal disorders in children from birth to 5 years: a cohort
study. Clin Gastroenterol Hepatol. 2007; 5(2): 186-91. doi: 10.1016/j.cgh.2006.06.012. PMID: 16901769.
Breckan RK, Asfeldt AM, Straume B, Florholmen J, Paulssen EJ. Prevalence, comorbidity, and risk factors
for functional bowel symptoms: a population-based survey in Northern Norway. Scand J Gastroenterol.
; 47(11): 1274-82. doi: 10.3109/00365521.2012.688215. PMID: 23061445.
Monnikes H, Schwan T, Rensburg C, Straszak A, Theek C, Sander P, et al. Randomised clinical trial:
sustained response to PPI treatment of symptoms resembling functional dyspepsia and irritable bowel
syndrome in patients suffering from an overlap with erosive gastro-oesophageal reflux disease. Aliment
Pharmacol Ther. 2012; 35(11): 1279-89. doi: 10.1111/j.1365-2036.2012.05085.x. PMID: 22486552.
Yamaji Y, Isomura Y, Yoshida S, Yamada A, Hirata Y, Koike K. Randomized controlled trial comparing
the efficacy of mosapride plus omeprazole combination therapy to omeprazole monotherapy in
gastroesophageal reflux disease. J Dig Dis. 2014; 15(9): 469-76. doi: 10.1111/1751-2980.12167. PMID:
Remes-Troche JM, Sobrino-Cossio S, Soto-Perez JC, Teramoto-Matsubara O, Morales-Arambula M,
Orozco-Gamiz A, et al. Efficacy, Safety, and Tolerability of Pantoprazole Magnesium in the Treatment of
Reflux Symptoms in Patients with Gastroesophageal Reflux Disease (GERD): A Prospective, Multicenter,
Post-Marketing Observational Study. Clin Drug Investig. 2014; 34(2): 83-93. doi: 10.1007/s40261-013- 0135-4. PMID: 24347282. 29) Moraes-Filho JP, Pedroso M, Quigley EMM. Randomised clinical trial: daily pantoprazole magnesium 40
mg vs. esomeprazole 40 mg for gastro-oesophageal reflux disease, assessed by endoscopy and symptoms.
Aliment Pharmacol Ther. 2014; 39(1): 47-56. doi: 10.1111/apt.12540. PMID: 24299323.
Yu YY, Fang DC, Fan LL, Chang H, Wu ZL, Cao Y, et al. Efficacy and safety of esomeprazole with
flupentixol/melitracen in treating gastroesophageal reflux disease patients with emotional disorders. J
Gastroenterol Hepatol. 2014; 29(6): 1200-6. PMID: 24955450.
Abbasinazari M, Panahi Y, Mortazavi SA, Fahimi F, Valizadegan G, Mohtashami R, et al. Effect of a
Combination of Omeprazole Plus Sustained Release Baclofen Versus Omeprazole Alone on Symptoms of
Patients with Gastroesophageal Reflux Disease (GERD). Iran J Pharm Res. 2014; 13(4): 1221-6. PMID:
, PMCID: PMC4232787.
Orbelo DM, Enders FT, Romero Y, Francis DL, Achem SR, Dabade TS, et al. Once-daily
omeprazole/sodium bicarbonate heals severe refractory reflux esophagitis with morning or nighttime
dosing. Dig Dis Sci. 2015; 60(1): 146-62. doi: 10.1007/s10620-013-3017-y. PMID: 24448652.
Nagahara A, Hojo M, Asaoka D, Sasaki H, Watanabe S. A randomized prospective study comparing the
efficacy of on-demand therapy versus continuous therapy for 6 months for long-term maintenance with
omeprazole 20 mg in patients with gastroesophageal reflux disease in Japan. Scand J Gastroenterol. 2014;
(4): 409-17. doi: 10.3109/00365521.2013.878380. PMID: 24444414, PMCID: PMC4002634.
Kim SE, Kim N, Oh S, Kim HM, Park MI, Lee DH, et al. Predictive Factors of Response to Proton Pump
Inhibitors in Korean Patients With Gastroesophageal Reflux Disease. J Neurogastroenterol Motil. 2015;
(1): 69-77. doi: 10.5056/jnm14078. PMCID: PMC4288103, PMCID: PMC4288103.
de Milliano I, Tabbers MM, van der Post JA, Benninga MA. Is a multispecies probiotic mixture effective in
constipation during pregnancy? 'A pilot study'. Nutr J. 2012; 11(8): 1-6. doi: 10.1186/1475-2891-11-80.
PMID: 23035837, PMCID: PMC3502183. 36) Perry KA, Pham TH, Spechler SJ, Hunter JG, Melvin WS, Velanovich V. 2014 SSAT State-of-the-Art
Conference: Advances in Diagnosis and Management of Gastroesophageal Reflux Disease. J Gastrointest
Surg. 2015; 19(3): 458-66. doi: 10.1007/s11605-014-2724-9. PMID: 25519085.
Boltin D, Boaz M, Aizic S, Sperber A, Fass R, Niv Y, et al. Psychological distress is not associated with
treatment failure in patients with gastroesophageal reflux disease. J Psychosom Res. 2013; 75(5): 462-6.
doi: 10.1016/j.jpsychores.2013.08.008. PMID: 24182636.
Sakamoto Y, Inamori M, Iwasaki T, Lida H, Endo H, Hosono K, et al. Relationship between upper
gastrointestinal symptoms and diet therapy: examination using frequency scale for the symptoms of
gastroesophageal reflux disease. Hepatogastroenterology. 2009; 57(104): 1635-8. PMID: 21443134.
Heine RG. Allergic gastrointestinal motility disorders in infancy and early childhood. Pediatr Allergy
Immunol. 2008; 19(5): 383-91. doi: 10.1111/j.1399-3038.2008.00785.x. PMID: 18713339.
Butt AK, Hashemy I. Risk factors and prescription patterns of gastroesophageal reflux disease: HEAL
study in Pakistan. J Pak Med Assoc. 2014; 64(7): 751-7. PMID: 25255580.
Kawano S, Murata H, Tsuji S, Kubo M, Tatsuta M, Iishi H, et al. Randomized comparative study of
omeprazole and famotidine in reflux esophagitis. J Gastroenterol Hepatol. 2002; 17(9): 955-9. PMID:
Metz DC, Bochenek WJ. Pantoprazole maintenance therapy prevents relapse of erosive oesophagitis.
Aliment Pharmacol Ther. 2003; 17(1): 155-64. PMID: 12492745.
Inadomi JM, McIntyre L, Bernard L, Fendrick AM. Step-down from multiple-to single-dose proton pump
inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved
with PPIs. Am J Gastroenterol. 2003; 98(9): 1940-4. doi: 10.1111/j.1572-0241.2003.07665.x. PMID:
Saitoh T, Otsuka H, Kawasaki T, Endo H, Iga D, Tomimatsu M, et al. Influences of CYP2C19
polymorphism on recurrence of reflux esophagitis during proton pump inhibitor maintenance therapy.
Hepatogastroenterology. 2009; 56(91-92): 703-6. PMID: 19621685.
Bate CM, Green JRB, Axon ATR, Tildesley G, Murray FE, Owen SM, et al. Omeprazole is more effective
than cimetidine in the prevention of recurrence of GERD-associated heartburn and the occurrence of
underlying oesophagitis. Aliment Pharmacol Ther. 1998; 12: 41-7. PMID: 9692699.
Usai P, Manca R, Cuomo R, Lai MA, Russo L, Boi MF. Effect of gluten-free diet on preventing recurrence
of gastroesophageal reflux disease-related symptoms in adult coeliacpatients with nonerosive reflux
disease. J Gastroenterol Hepatol. 2008; 23(9): 1368-72. doi: 10.1111/j.1440-1746.2008.05507.x. PMID:
Miyake S, Yamada M, Iwamoto H, Yamashita S, Sugio Y. Effect of a new H2-blocker, famotidine, in
reflux esophagitis among severely handicapped children. Clin ther. 1986; 9(5): 548-58. PMID: 2889529.
Caro JJ, Salas M, Ward A. Healing and relapse rates in gastroesophageal reflux disease treated with the
newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole,
ranitidine, and placebo: evidence from randomized clinical trials. Clin ther. 2001; 23(7): 998-1017. PMID:
Published
Issue
Section
License
Copyright (c) 2020 KNOWLEDGE KINGDOM PUBLISHING
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
